Fractyl Health Earnings Call: Revita Nears Key Pivotal Test

Fractyl Health, Inc. ((GUTS)) has held its Q4 earnings call. Read on for the main highlights of the call.

Fractyl Health’s latest earnings call struck a cautiously optimistic tone, with management emphasizing strong clinical momentum and constructive regulatory dialogue despite a widening net loss and a finite cash runway. Executives argued that compelling Revita data, a fully enrolled pivotal trial, and a clear path toward reimbursement collectively outweigh execution risks around procedure standardization and future financing.

Clear Dose-Response Strengthens Revita’s Clinical Story

Revita’s weight-maintenance effect showed a statistically significant, monotonic dose-response, linking longer duodenal ablation to better outcomes. Patients receiving more than 14 cm of ablation regained roughly half the weight of the sham group, and an optimized subgroup saw weight regain of 2.9% versus 9.9% in sham, a roughly 70% reduction.

Pivotal REMAIN-1 Trial Fully Enrolled and Well-Powered

The REMAIN-1 pivotal cohort has randomized more than 300 participants across over 30 sites and more than 20 operators, making it one of the largest sham-controlled GI endoscopy pivotal trials. Management highlighted that the study is powered above 90% to hit two co-primary endpoints, supporting confidence in the upcoming readout.

Operational Metrics Underscore Trial Integrity

Retention in the pivotal exceeds 95%, while resumption rates for weight-loss medications are running below internal assumptions, which supports clean data collection. The blinded safety profile remains consistent with prior Revita studies, reinforcing feasibility and reducing worries about unexpected adverse events.

Training and Procedural Scalability Look Achievable

In the pivotal study, mean and median ablation lengths exceed 16 cm, and investigators are consistently achieving the more than 14 cm threshold linked to better outcomes. The company says endoscopists typically need only three to four procedures to reach consistent performance, suggesting Revita could scale operationally if approved.

Early FDA Feedback Favors De Novo Route

Regulators have reviewed safety data and indicated that Revita appears consistent with a Class II moderate-risk De Novo device, avoiding a more burdensome PMA path. Fractyl plans to file a De Novo submission in late fourth quarter 2026 with six-month pivotal data in hand, targeting a more capital-efficient regulatory strategy.

Commercial and Reimbursement Strategy Takes Shape

Management is preparing a Category III CPT application this summer, with an anticipated effective date around mid-2027 to support coding for the procedure. The company also plans to seek CMS transitional pass-through payment to cover disposables, aiming to give hospitals a positive contribution margin around launch and ease early adoption.

Rejuva Pipeline Progresses Without Draining Revita Capital

Fractyl’s Rejuva RNA program advanced as clinical trial applications for RJVA-001 in type 2 diabetes were submitted in Europe and Australia, with feedback expected in the second quarter of 2026. First-in-human dosing and preliminary data are anticipated in the second half of 2026, under a funding framework designed not to divert resources from Revita.

Cost Controls Improve Operating Efficiency

R&D expenses fell to $16.5 million in the fourth quarter of 2025 from $20.3 million a year earlier, an almost 19% decline attributed to strategic reprioritization. Adjusted EBITDA improved modestly, with a loss of $21.2 million versus a $22.1 million loss in the year-ago quarter, signaling early benefits from tighter spending.

Cash Covers Key Milestones but Leaves a Tight Runway

The company ended 2025 with $81.5 million in cash and equivalents, plus $4.1 million from warrant exercises, for roughly $85.6 million in total. Management believes this funds operations into early 2027, enough to deliver pivotal data and a De Novo submission but leaving limited cushion for commercialization without new capital.

Headline Net Loss Jumps on Noncash Items

Fractyl reported a fourth-quarter 2025 net loss of $43.7 million, up sharply from $25.0 million a year earlier, a roughly 75% increase that may unsettle some investors. The company attributed $20.2 million of that jump to a noncash change in warrant liabilities, but the higher headline loss still highlights the cost of advancing its programs.

Execution Risks from Procedural Variability and Paused Programs

Midpoint cohort data showed weaker six-month effects versus three months, driven by site-level variability in ablation length, underscoring how outcomes hinge on procedural “dose” and training. R&D cuts were also aided by pausing the REVITALIZE-1 study, signaling pipeline reprioritization and the possibility of delays in non-core programs.

Regulatory and Reimbursement Timing Still a Swing Factor

Despite favorable early FDA feedback on De Novo classification, ultimate clearance depends on meeting efficacy endpoints and successfully completing the submission. Even with a Category III CPT code targeted for mid-2027 and transitional pass-through, there remains a timing gap before widespread reimbursement, which could slow initial uptake.

Guidance Highlights a Catalyst-Rich but Compressed 2026–2027 Window

Management guided to a busy 2026, with six-month top-line data from REMAIN-1 expected in early fourth quarter and a De Novo filing planned for late in the same quarter, while Rejuva’s first-in-human data should emerge in the second half. Financially, Fractyl plans to operate into early 2027 without raising capital before the pivotal readout, while pushing forward its reimbursement strategy via a CPT filing this summer and planned pass-through requests.

Fractyl’s call painted a picture of a company nearing a major inflection, with robust Revita data, high-quality execution in a large pivotal trial, and a credible regulatory and reimbursement roadmap. Investors will need to balance those strengths against a widening net loss, a limited cash runway beyond early 2027, and real-world training risks, but the risk-reward now hinges squarely on the pivotal REMAIN-1 results and De Novo outcome.